The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer.
Nelczyk AT, Ma L, Gupta AD, Gamage HEV, McHenry MT, Henn MA, Kadiri M, Wang Y, Krawczynska N, Bendre S, et al. Biochim Biophys Acta Mol Basis Dis. 2022 Nov 1; 1868(11):166515. Epub 2022 Aug 4.